Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeFirst statedLatest Governance (2026-10-01): "Restated"

Target Discovery in Women's Health With Insilico Medicine

First written in FY2026. 1 of 4 entries say "Advanced", first in 2026-05-11. Latest entry: 2026-10-01.

4entries
1years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst stated2026-03-24Advanced2026-05-11First statedFY2026 – 2026-10-012026: 42026
Same theme, other companies
Insilico Medicine Women's Health Target Discovery PartnershipA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. 2026-10-01RestatedGovernance

    「Insilico Medicine 社との協業を通じて、AIを活用した婦人科疾患領域の新規創薬ターゲット探索を推進するなど、AI 創薬技術の導入を着実に加速しています。」

    AIを活用した女性健康領域の標的探索について、創薬研究基盤の一部として再確認している。
  2. FY2026First statedAnnual report

    「In March 2026, we expanded our partnership with Insilico Medicine for the discovery of novel targets related to women’s health.」

    女性の健康に関する新規標的探索について、Insilico Medicineとのパートナーシップを2026年3月に拡大した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Governance of 2026-10-01: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.